SODIUM OXYBATE by Hikma is depressant. Approved for cataplexy, excessive daytime sleepiness (eds) in patients with narcolepsy. First approved in 2017.
Drug data last refreshed 19h ago
depressant. The mechanism of action of sodium oxybate oral solution in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the therapeutic effects of…
Worked on SODIUM OXYBATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
Sodium Oxybate in Patients With Chronic Fatigue Syndrome.
Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)